|
Drugs with significant reduction in HPRT1 expression post treatment
|
|
HT29
|
AS-703026
|
Mitogen-activated protein kinase
|
MEK
|
− 9.822
|
|
HUES3
|
OTS-167
|
Maternal embryonic leucine-zipper kinase
|
MELK
|
− 9.707
|
|
Jurkat
|
BGT-226
|
Phosphoinositide 3-kinase
|
P13K
|
− 8.533
|
|
MCF7
|
genz-644282
|
Topoisomerase I
|
Topo I
|
− 7.601
|
|
A375
|
AS-703026
|
Mitogen-activated protein kinase
|
MEK
|
− 7.119
|
|
MCF7
|
SN-38
|
Topoisomerase I
|
Topo I
|
− 6.904
|
|
A375
|
SN-38
|
Topoisomerase I
|
Topo I
|
− 6.702
|
|
HT29
|
TAK-733
|
Mitogen-activated protein kinase
|
MEK
|
− 6.594
|
|
MCF7
|
Paclitaxel
|
Microtubule function
|
–
|
− 6.537
|
|
MCF7
|
KX2-391
|
Sarcome
|
Src
|
− 6.366
|
|
Drugs with an increase in HPRT1 expression post treatment
|
|
MNEU
|
Dinaciclib
|
Cyclin dependent kinase
|
CDK
|
2.362
|
|
NPC
|
SB-939
|
Histone deacetylase
|
HDAC
|
2.39
|
|
MNEU
|
Mitoxantrone
|
Topoisomerase II
|
Topo II
|
2.412
|
|
NEU
|
Ischemin
|
P53 transcription
|
–
|
2.454
|
|
ASC
|
Mitoxantrone
|
Inflammation
|
–
|
2.551
|
|
NEU
|
NVP-BGJ398
|
Fibroblast growth factor receptor
|
FGFR
|
2.668
|
|
Jurkat
|
Tanespimycin
|
Heat shock protein
|
HSP
|
2.72
|
|
SKL
|
Dinaciclib
|
Cyclin dependent kinase
|
CDK
|
3.137
|
|
ASC
|
Dinaciclib
|
Cyclin dependent kinase
|
CDK
|
3.195
|
|
Jurkat
|
Dinaciclib
|
Cyclin dependent kinase
|
CDK
|
5.414
|
